| # | Drug | Count |
|---|---|---|
| 0 | TRAMETINIB | 491 |
| 1 | DABRAFENIB | 481 |
| 2 | NIVOLUMAB | 178 |
| 3 | IPILIMUMAB | 153 |
| 4 | PREDNISONE | 147 |
| 5 | PEMBROLIZUMAB | 137 |
| 6 | SILDENAFIL CITRATE | 119 |
| 7 | TALIMOGENE LAHERPAREPVEC | 115 |
| 8 | VEMURAFENIB | 103 |
| 9 | DEXAMETHASONE | 102 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TALIMOGENE LAHERPAREPVEC | 115 | 0.0724 |
| 1 | DABRAFENIB | 481 | 0.0227 |
| 2 | TRAMETINIB | 491 | 0.0202 |
| 3 | ALDESLEUKIN | 24 | 0.0190 |
| 4 | CEFADROXIL | 18 | 0.0088 |
| 5 | VEMURAFENIB | 103 | 0.0086 |
| 6 | COBIMETINIB | 31 | 0.0070 |
| 7 | BINIMETINIB | 45 | 0.0057 |
| 8 | SARGRAMOSTIM | 9 | 0.0052 |
| 9 | DACARBAZINE | 39 | 0.0052 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 349 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 295 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 166 |
| 3 | Kinase Inhibitor [EPC] | 161 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 154 |
| 5 | Alkylating Drug [EPC] | 143 |
| 6 | Tumor Necrosis Factor Blocker [EPC] | 132 |
| 7 | Benzodiazepine [EPC] | 97 |
| 8 | Proton Pump Inhibitor [EPC] | 85 |
| 9 | HMG-CoA Reductase Inhibitor [EPC] | 74 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Growth Factor [EPC] | 24 | 0.0190 |
| 1 | Lymphocyte Activation Gene-3 Blocker [EPC] | 4 | 0.0078 |
| 2 | Tubulin Inhibiting Agent [EPC] | 1 | 0.0034 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 154 | 0.0032 |
| 4 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 295 | 0.0030 |
| 5 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 6 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 7 | CD38-directed Cytolytic Antibody [EPC] | 9 | 0.0015 |
| 8 | Provitamin D2 Compound [EPC] | 42 | 0.0014 |
| 9 | beta Lactamase Inhibitor [EPC] | 6 | 0.0013 |